Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs

Carcinogenesis

Volumn 36, Issue 2, 2014, Pages 291-298

  Fink, Stephen P ^a,b   Dawson, Dawn M ^a   Zhang, Yongyou ^a,b   Kresak, Adam ^a,b   Lawrence, Earl G ^a,b   Yang, Peiying ^c   Chen, Yanwen ^b   Barnholtz Sloan, Jill S ^b   Willis, Joseph E ^a,b   Kopelovich, Levy ^d   Markowitz, Sanford D ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ACETYLSALICYLIC ACID; AZOXYMETHANE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PROSTAGLANDIN E2; SULINDAC; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; ANTINEOPLASTIC AGENT; CARCINOGEN; CYCLOOXYGENASE 2 INHIBITOR; MEMBRANE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PTGS1 PROTEIN, MOUSE; PTGS2 PROTEIN, MOUSE; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PREVENTION; CHEMOPROPHYLAXIS; COLITIS; COLON ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR RESISTANCE; ANIMAL; CHEMICALLY INDUCED; COLONIC NEOPLASMS; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INFLAMMATION; INTESTINE MUCOSA; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; ASPIRIN; AZOXYMETHANE; CARCINOGENS; CELECOXIB; CHEMOPREVENTION; COLONIC NEOPLASMS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; HYDROXYPROSTAGLANDIN DEHYDROGENASES; INFLAMMATION; INTESTINAL MUCOSA; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; PYRAZOLES; SULFONAMIDES; SULINDAC;

EID: 84928192343     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu241     Document Type: Article

References (38)

1. Siegel, R. et al. (2012) Cancer statistics, 2012. Cancer J. Clin., 62, 10-29.
2. Markowitz, S.D. (2008) Colorectal neoplasia goes with the flow: prostaglandin transport and termination. Cancer Prev. Res. (Phila)., 1, 77-79.
3. Markowitz, S.D. et al. (2009) Molecular origins of cancer: molecular basis of colorectal cancer. N. Engl. J. Med., 361, 2449-2460.
4. Brown, J.R. et al. (2005) COX-2: a molecular target for colorectal cancer prevention. J. Clin. Oncol., 23, 2840-2855.
5. Gupta, R.A. et al. (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer, 1, 11-21.
6. Markowitz, S.D. (2007) Aspirin and colon cancer-targeting prevention? N. Engl. J. Med., 356, 2195-2198.
7. Tai, H.H. et al. (2006) NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions. Curr. Pharm. Des., 12, 955-962.
8. Myung, S.J. et al. (2006) 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc. Natl Acad. Sci. USA, 103, 12098-12102.
9. Oshima, M. et al. (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803-809.
10. Baron, J.A. et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med., 348, 891-899.
11. Bertagnolli, M.M. et al. (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med., 355, 873-884.
12. Burn, J. et al. (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet, 378, 2081-2087.
13. Meyskens, Jr. F.L.et al. (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev. Res. (Phila)., 1, 32-38.
14. Sandler, R.S. et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med., 348, 883-890.
15. Marnett, L.J. (2009) The COXIB experience: a look in the rearview mirror. Annu. Rev. Pharmacol. Toxicol., 49, 265-290.
16. Thun, M.J. et al. (1991) Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 325, 1593-1596.
17. Yan, M. et al. (2009) 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc. Natl Acad. Sci. USA, 106, 9409-9413.
18. Coggins, K.G. et al. (2002) Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus. Nat. Med., 8, 91-92.
19. Carothers, A.M. et al. (2006) Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor. Cancer Res., 66, 6432-6438.
20. Williams, C.S. et al. (2000) Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res., 60, 6045-6051.
21. Beazer-Barclay, Y. et al. (1996) Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis, 17, 1757-1760.
22. Williamson, S.L. et al. (1999) Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months. Carcinogenesis, 20, 805-810.
23. Nambiar, P.R. et al. (2003) Preliminary analysis of azoxymethane induced colon tumors in inbred mice commonly used as transgenic/ knockout progenitors. Int. J. Oncol., 22, 145-150.
24. Newmark, H.L. (1987) Nutrient density: an important and useful tool for laboratory animal studies. Carcinogenesis, 8, 871-873.
25. Chan, A.T. et al. (2012) Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev. Res. (Phila)., 5, 164-178.
26. Chan, A.T. et al. (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N. Engl. J. Med., 356, 2131-2142.
27. Fink, S.P. et al. (2013) Colonic 15-PGDH levels are stable across distance and time and are not perturbed by aspirin intervention. Dig. Dis. Sci., 58, 2615-2622.
28. Reddy, B.S. (2004) Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. Environ. Mol. Mutagen., 44, 26-35.
29. Reddy, B.S. et al. (1993) Inhibitory effect of aspirin on azoxymethaneinduced colon carcinogenesis in F344 rats. Carcinogenesis, 14, 1493-1497.
30. Mladenova, D. et al. (2011) The NSAID sulindac is chemopreventive in the mouse distal colon but carcinogenic in the proximal colon. Gut, 60, 350-360.
31. Itano, O. et al. (2009) Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations. Carcinogenesis, 30, 1923-1926.
32. Carothers, A.M. et al. (2010) Persistent cyclooxygenase-2 inhibition downregulates NF-{kappa}B, resulting in chronic intestinal inflammation in the min/+ mouse model of colon tumorigenesis. Cancer Res., 70, 4433-4442.
33. Davids, J.S. et al. (2010) Chronic cyclooxygenase-2 inhibition promotes myofibroblast-associated intestinal fibrosis. Cancer Prev. Res. (Phila)., 3, 348-358.
34. Kaufmann, H.J. et al. (1987) Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann. Intern. Med., 107, 513-516.
35. Thiéfin, G. et al. (2005) Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum. Joint Bone Spine, 72, 286-294.
36. Greenspan, E.J. et al. (2010) Molecular alterations associated with sulindac-resistant colon tumors in ApcMin/+ mice. Cancer Prev. Res. (Phila)., 3, 1187-1197.
37. Yang, W. et al. (2001) p21(WAF1/cip1) is an important determinant of intestinal cell response to sulindac in vitro and in vivo. Cancer Res., 61, 6297-6302.
38. Yao, H. et al. (2008) Disruption of p21 attenuates lung inflammation induced by cigarette smoke, LPS, and fMLP in mice. Am. J. Respir. Cell Mol. Biol., 39, 7-18.